Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2011 1
2013 1
2015 1
2017 2
2018 3
2019 1
2020 3
2021 2
2023 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Choueiri TK, et al. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.
Anido-Herranz U, Fernandez-Calvo O, Ruiz-Bañobre J, Martinez-Breijo S, Fernandez-Nuñez N, Nogareda-Seoane Z, Garrido-Pumar M, Casas-Nebra J, Muñiz-Garcia G, Portela-Pereira P, Gomez-Caamaño A, Perez-Fentes DA, Santome-Couto L, Lázaro M, Molina-Diaz A, Medina-Colmenero A, Vazquez-Estevez S. Anido-Herranz U, et al. Front Oncol. 2024 May 7;14:1385466. doi: 10.3389/fonc.2024.1385466. eCollection 2024. Front Oncol. 2024. PMID: 38774416 Free PMC article.
Approach of the patient with renal cancer: Is there a collaboration between urology and oncology?
Sabell Pérez-Salgado F, Vázquez-Estévez S, Anido-Herranz U, Blanco-Parra M, Casas-Nebra FJ, Fernández-Calvo O, Lázaro-Quintela M, López-García S. Sabell Pérez-Salgado F, et al. Among authors: anido herranz u. Actas Urol Esp (Engl Ed). 2018 Jan-Feb;42(1):1-4. doi: 10.1016/j.acuro.2017.04.001. Epub 2017 Jun 3. Actas Urol Esp (Engl Ed). 2018. PMID: 28587846 English, Spanish. No abstract available.
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, Rodríguez Martínez de Llano S, Lázaro Quintela M, León Mateos L, Vázquez Estévez S, Antón Aparicio LM. Anido Herranz U, et al. Expert Rev Anticancer Ther. 2015 Mar;15(3):339-48. doi: 10.1586/14737140.2015.999045. Epub 2015 Jan 2. Expert Rev Anticancer Ther. 2015. PMID: 25555355 Free article. Review.
A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma.
Betancor YZ, Ferreiro-Pantín M, Anido-Herranz U, Fuentes-Losada M, León-Mateos L, García-Acuña SM, Vaamonde-Rodríguez V, García-Pinel B, Cebey-López V, Villaverde-Viaño R, Lombardía-Rodríguez H, Kotrulev M, Fernández-Díaz N, Gomez-Tourino I, Fernández-Baltar C, García-González J, Tubio JMC, López-López R, Ruiz-Bañobre J. Betancor YZ, et al. Among authors: anido herranz u. Front Immunol. 2024 Apr 10;15:1374728. doi: 10.3389/fimmu.2024.1374728. eCollection 2024. Front Immunol. 2024. PMID: 38660294 Free PMC article.
Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer.
Fernández Calvo O, Muñoz Iglesias J, Abou Jokh Casas E, Molina-Díaz A, Anido Herranz U, Casas Nebra J, García-Bernardo L, Martínez-Breijo S, Lázaro-Quintela M, Muñiz-García G, Vázquez-Estevez S. Fernández Calvo O, et al. Among authors: anido herranz u. Clin Transl Oncol. 2024 Sep 12. doi: 10.1007/s12094-024-03662-7. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39266875 Review.
Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study.
Juan Fita MJ, Anido Herranz U, Mendez-Vidal MJ, Gironés-Sarrió R, Muñoz-Langa J, Sepúlveda-Sánchez J, Mellado B, Alvarez-Fernandez C, Heras López L, López-Guerrero JA, García-Casado Z, Calatrava A, Ángel Climent M. Juan Fita MJ, et al. Among authors: anido herranz u. Cancers (Basel). 2023 Oct 31;15(21):5223. doi: 10.3390/cancers15215223. Cancers (Basel). 2023. PMID: 37958398 Free PMC article.
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Carretero-González A, Lora D, Martín Sobrino I, Sáez Sanz I, Bourlon MT, Anido Herranz U, Martínez Chanzá N, Castellano D, de Velasco G. Carretero-González A, et al. Among authors: anido herranz u. Cancers (Basel). 2020 Jul 17;12(7):1945. doi: 10.3390/cancers12071945. Cancers (Basel). 2020. PMID: 32709062 Free PMC article. Review.
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
Ferreiro-Pantín M, Anido-Herranz U, Betancor YZ, Cebey-López V, León-Mateos L, García-González J, García-Acuña SM, Fernández-Díaz N, Tubio JMC, López-López R, Ruiz-Bañobre J. Ferreiro-Pantín M, et al. Among authors: anido herranz u. ESMO Open. 2023 Aug;8(4):101611. doi: 10.1016/j.esmoop.2023.101611. Epub 2023 Jul 27. ESMO Open. 2023. PMID: 37516059 Free PMC article. Clinical Trial.
20 results